Cabometyx (cabozantinib tablets) — Cigna
Hepatocellular carcinoma
Initial criteria
- Patient age ≥ 18 years
- Patient has been previously treated with at least one systemic regimen (e.g., Tecentriq [atezolizumab], bevacizumab, Imjudo [tremelimumab], Imfinzi [durvalumab], sorafenib, Lenvima [lenvatinib], or Opdivo [nivolumab])
Approval duration
1 year